Genialis is a technology company.
Genialis has raised $15.0M across 2 funding rounds.
Genialis has raised $15.0M in total across 2 funding rounds.
Genialis has raised $15.0M in total across 2 funding rounds.
Genialis's investors include First Star Ventures, INBlockchain, SOSV, Uncorrelated Ventures.
Genialis is a precision oncology company leveraging AI and RNA biomarkers to advance cancer drug development and personalized medicine. It builds AI models, including the Genialis Supermodel trained on over one billion RNA-seq data points, to predict patient responses, stratify clinical trials, identify mechanisms of action, and address drug resistance, serving pharmaceutical and diagnostics companies.[1][2][4] By analyzing why some patients respond to therapies while others do not, Genialis tackles key challenges like high clinical trial failure rates and ineffective cancer treatments, delivering actionable insights for better outcomes.[2][4]
The company focuses on translational research, partnering with biopharma leaders like Debiopharm to derisk drug development and guide precision medicine decisions.[1][4] Its growth includes presentations at major conferences like AACR 2025, showcasing predictive capabilities across drug targets and tumor types, with a foundation in a globally diverse dataset and proprietary methodology.[2][4]
Genialis was founded in 2015 and is headquartered in Boston, Massachusetts, positioning it at the intersection of computational biology and oncology innovation.[1] While specific founders are not detailed in available sources, the company emerged from expertise in RNA biomarkers and machine learning to address gaps in cancer treatment efficacy.[1][2] Early focus centered on discovering biomarkers using AI to support oncology drug positioning and diagnostics, evolving into a full precision medicines platform with the development of its Supermodel.[1][4]
Pivotal moments include building a massive dataset of RNA-seq data and proprietary AI methodologies, enabling rapid insights into patient biology and drug performance.[2][4] By 2025, Genialis highlighted its technology at AACR, demonstrating predictive power for therapeutic responses, marking its rise in the precision oncology space.[4]
Genialis rides the wave of AI-driven precision oncology, where machine learning deciphers complex cancer biology amid rising demands for personalized treatments and efficient drug development.[1][2][4] Timing aligns with explosive growth in multi-omics data and foundation models for biology, similar to trends in competitors like Caris Life Sciences (molecular profiling) and BioMap (AI life sciences), but Genialis specializes in RNA-centric AI for actionable oncology insights.[1]
Market forces favoring it include high clinical trial failure rates (most molecules fail) and low patient response rates to cancer drugs, amplified by biopharma's push for biomarkers to cut costs and speed approvals.[2] Genialis influences the ecosystem by partnering with pharma giants, accelerating therapies in oncology, and setting standards for AI in translational research, potentially reshaping how drugs move from lab to clinic.[1][4]
Genialis is poised to expand its Supermodel applications, likely deepening pharma partnerships and launching companion diagnostics as AI biology models mature.[2][4] Trends like multimodal AI integration (e.g., combining RNA with other omics) and regulatory embrace of digital twins will propel its growth, especially in high-unmet-need areas like resistance prediction.[1][4] Its influence may evolve from biomarker specialist to key enabler in oncology pipelines, amplifying impact as precision medicine scales globally—turning data into lives saved, much like its mission to make promising molecules life-saving realities.[2]
Genialis has raised $15.0M across 2 funding rounds. Most recently, it raised $13.0M Series A in March 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2023 | $13.0M Series A | First Star Ventures, INBlockchain, SOSV, Uncorrelated Ventures | |
| Nov 1, 2017 | $2.0M Seed | First Star Ventures, INBlockchain, SOSV, Uncorrelated Ventures |